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Abstract: Dry eye syndrome is a complex and insidious pathology with a high level of prevalence
among the human population and with a consequently high impact on quality of life and
economic cost. Currently, its treatment is symptomatic, mainly based on the control of lubrication
and inflammation, with significant limitations. Therefore, the latest research is focused on the
development of new biological strategies, with the aim of regenerating affected tissues, or at least
restricting the progression of the disease, reducing scar tissue, and maintaining corneal transparency.
Therapies range from growth factors and cytokines to the use of different cell sources, in particular
mesenchymal stem cells, due to their multipotentiality, trophic, and immunomodulatory properties.
We will review the state of the art and the latest advances and results of these promising treatments
in this pathology.
Keywords: mesenchymal stem cell; allogenic cell therapy; growth factor; lacrimal gland; dry eye;
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1. Introduction
Dry eye disease (DED) has been defined as a multifactorial disease of the ocular surface
characterized by a loss of homeostasis of the tear film, and is accompanied by ocular symptoms
in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and
neurosensory abnormalities play etiological roles [1]. This pathology is also often secondary to a
multisystem autoimmune disease such as Sjögren’s Syndrome, rheumatoid arthritis, systemic lupus
erythematosus, etc., and is a source of frustration for professionals and patients [2–7].
One study found that the prevalence of DED ranged from approximately 5% to 50% [8], with
higher rates among women and the elderly [4,6,9]. Consequently, DED is an important public health
problem that leads to a sanitary high cost, hinders the performance of the activities of daily living, and
therefore decreases quality of life [2–7].
Recently, it was agreed by the Tear Film and Ocular Surface Society (TFOS) International Dry
Eye Workshop (DEWS) that tear hyperosmolarity and tear instability are the core drivers of DED.
This allowed two major subtypes to be defined: evaporative dry eye (EDE), where tear hyperosmolarity
is the result of an excessive evaporation of the tear film in the presence of normal lacrimal function; and
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aqueous-deficient dry eye (ADDE), where hyperosmolarity results from a reduced lacrimal secretion
in the presence of a normal rate of tear evaporation [10].
Although its pathophysiology is still unclear, the Committee for the International Dry Eye
Workshop highlighted the crucial roles of hyperosmolarity and inflammation in DED [1]. In certain
conditions, there is an increase in the osmolarity of the tear film, either due to poor tear function or to
excessive evaporation of the aqueous tear component, with normal lacrimal secretory function [1,2,5].
This triggers a hyperosmotic state of the ocular surface, which initiates an inflammatory response
involving both innate and adaptive immune systems [1,4,5,8].
Despite the multifactorial nature of DED, this disease can be chronically self-maintained through
a vicious cycle [10], where the epithelial damage secondary to the hyperosmolar state causes
exposure and chronic stimulation of corneal nerve endings. Reduction in corneal sensitivity promotes
neurogenic stress, contributing to the impairment of ocular surface homoeostasis and the release
of proinflammatory factors responsible for greater damage to the ocular surface and to the gland
itself [4,8,10].
An inflamed lacrimal gland may produce abnormal tears containing proinflammatory cytokines,
disrupting the ocular surface, activating angiogenesis and lymphangiogenesis, and exacerbating the
inflammatory response. This perpetuates a chronic inflammatory process responsible for the ocular
surface damage, visual impairment, and other associated symptoms [1,4,10].
Squamous metaplasia of the epithelial cells on the ocular surface occurs, with a gradual loss of
conjunctival goblet cells and an increase in inflammatory cells as well as an increase in the number of
apoptotic epithelial cells [4,8,10].
Currently, there is no cure for dry eye, and the treatments are directed towards improving the
symptoms in order to break the vicious circle of DED and to prevent chronicity and progression of the
disease [1,2,10].
The mainstay of conventional therapy is the application of artificial tears that increase
moisture on the ocular surface and provide additional lubrication [11]. Other pharmacological
approaches—anti-inflammatory and topical immunosuppressory—are used to improve the symptoms
of chronic inflammation [10]. Steroids are the most commonly prescribed short-term treatment
for managing DED-associated inflammation, but their long-term use is not recommended [1,10].
Cyclosporine A is an immunosuppressive peptide derived from fungal origin, and is used as an
anti-inflammatory topical drop for DED treatment. However, adverse ocular events have been
reported [2,10,12]. In recent years, new regenerative strategies have emerged that have made possible
a qualitative advance in the management of this pathology.
2. Hemoderivatives
The use of drops of different blood products in the DED treatment and other pathologies of the
ocular surface has resulted in a remarkable advance in the management of severe cases refractory to
conventional therapy [13–15]. Currently, the most common preparations are the use of autologous or
allogeneic serum drops, platelet-derived plasma products, and umbilical cord blood serum [16,17].
2.1. Autologous Serum (AS)
Serum is the liquid fraction of whole blood that is collected after the blood is allowed to clot.
The clot can be removed by centrifugation and the resulting supernatant—the serum—is prepared
for use as drops [15]. Autologous serum (AS) application was employed in 1975 to treat ocular alkali
injuries [18]. In 1984, its first successful use in patients with dry eye was described [19]. However,
from the works of Tsubota et al. [20,21] in 1999, AS application gained widespread acceptance as an
adjuvant therapy in different ocular surface disorders [3,15,22,23].
The therapeutic advantages of AS use as a substitute for tears are given by their similarity
in certain characteristics, such as pH, osmolality, and biomechanical characteristics. AS fulfills a
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lubricating function and performs anti-inflammatory, antimicrobial, and epitheliotrophic functions
through certain biomolecules of its composition similar to natural tears [13,23] (Table 1).
Table 1. Comparison of several components between natural tears and different hemoderivatives used
in corneal surface.
Component Tear AS PRP UCS
pH 7.4 7.4 6.61–7.26 7.4
Osmolarity 298–300 296 296 296
Water (%) 98 91 – –
Albumin (g/dL) 0.39 4–5.3 – –
Globulins (g/dL) 0.27 2.3 – –
EGF (ng/mL) 0.2–0.3 0.1–0.2 0.27–4.9 0.5
TGF-β (ng/mL) 2–10 6–33 6.4–67.3 57
NGF (pg/mL) 107.5–468 54–401 37.7 730
IGF-1 (ng/mL) 75.5–157 375 93.5 230
PDGF (ng/mL) 1.33 15–17 13–86 –
VEGF (pg/mL) – 34.7–160 60–124 –
Vitamin A (ng/mL) 16 372 – 231
Vitamin C (mg/mL) 0.117 0.02 – –
SP (pg/mL) 69.8–157 71–169 – 245
Lysozyme (mg/mL) 1.4 6 – 6
Surface IgA (µg/mL) 1190 2 – –
Fibronectin (µg/mL) 21 30–205 28.9–31.1 –
Lactoferrin (ng/mL) 1650 266 – –
Calcium (mmol/L) 0.3–2 2.5 – –
Potassium (mmol/L) 26–42 4.5 – –
Sodium (mmol/L) 120–170 140 – –
AS: autologous serum; EGF: epidermal growth factor; IGF-1: insulin-like growth factor 1; NGF: nerve growth factor;
PDGF: platelet-derived growth factors; PRP: platelet-rich plasma; SP: substance P; TGF-β: transforming growth
factor β; UCS: umbilical cord blood serum; VEGF: vascular endothelial growth factor.
In AS, composition is emphasized; various substances are present which also exist in normal
tears, including growth factors such as transforming growth factor (TGF-β), platelet-derived growth
factors (PDGF), epidermal growth factor (EGF), nerve growth factor, and insulin-like growth
factor 1; neurotrophic factors (substance P); cytokines; bacteriostatic factors (lactoferrin, lysozyme,
immunoglobulins); fibronectin and vitamin A and E [13,23,24] (Table 1). Some of them have an
increased concentration with respect to natural tears, such as vitamin A, lysozyme, TGF-β, and
fibronectin, and some components are present in lesser concentrations, such as immunoglobulin A,
epithelial EGF, and vitamin C [15,23,24].
TGF-β is known to have dose-dependent antiproliferative properties, and its average levels are
usually five times higher in AS than in natural tears, so it is usually used at 20% dilution to prevent the
potentially harmful effect of avoiding possible retardation of epithelial wound healing. Nonetheless,
dilution may reduce the concentration of other beneficial factors—particularly EGF and fibronectin,
which are proven to support the proliferation and migration of corneal epithelial cells [3,15,23–25].
Despite many clinical studies demonstrating their efficacy, there is no standard protocol for
obtaining AS [16,17]. Individual particularities, patient health status, collection of whole blood,
production protocol, dilution, storage, and treatment regimens, have been described as factors that
affect the composition and efficacy of the product, leading to variability in the results [7,15,26–28].
However, the presence of leucocytes during the AS preparation procedure increases the level of
pro-inflammatory cytokines (interleukin 6 (IL-6), IL-1β, and tumor necrosis factor-α (TNF-α), etc.),
added to the presence of immunoglobulins and complement, may be deleterious for many patients
suffering from immunological alterations [29].
Although some growth factors (e.g., EGF, TGF-β, and insulin-like growth factor 1 (IGF-1)) are
relatively stable, neurotrophic factors as substance P (SP) and calcitonin gene-related peptide (CGRP)
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significantly degraded at−15 ◦C in 6 weeks and at +4 ◦C in 24 h [15]. Thus, AS storage must be carried
out in freezer at −20 ◦C, and it must be thawed before use and kept in in the refrigerator at +4 ◦C if it
is to be stored for 24 h to a week. The serum eye drops must be used within three months of the date
of production [4,23,27]. It is important that vials containing AS be kept away from light to avoid the
degradation of vitamin A [15].
The AS tears regimen of daily application goes from hourly up to three times a day [13,15,26].
Preservatives are usually not added to AS, thus reducing the risk of preservative-induced toxicity.
However, a lack of preservatives theoretically increases the risk of ocular infections [14,23,26].
Few studies have directly compared clinical outcomes of different concentrations of AS [13,15,30].
Most published studies have reported the use of 20% AS eye drops for treating a number of ocular
surface conditions, mainly in dry eye, where AS suppresses apoptosis in the ocular surface epithelium
and increases goblet cell density in dry eye [23,30]. Nevertheless, its potential benefits have been
questioned by a recent meta-analysis [15].
Undiluted serum was more effective in epithelial cell migration and epithelial healing in
postoperative corneal epithelial defect following various ocular surgeries, probably because of the
higher concentration of fibronectin, shortening the healing time and decreasing the risk of chronic
epithelial defect and complications [14,28].
The TFOS DEWS II Management and Therapy Report shows a table with results from 14 clinical
studies on the efficacy of autologous serum in DED. Among these studies there is substantial variation
for production parameters, endpoints, dose frequency, and treatment duration. Sixty to eighty percent
of patients showed positive responses [31].
2.2. Allogeneic Serum (ALS)
ALS from healthy blood donors was used when a patient’s own serum was unsuitable, unavailable,
or where repeated blood sampling was not possible, including patients with viral infection, septicemia,
severe anemia, and elderly patients with multiple systemic diseases [7,17,26].
ALS use offers an additional advantage in some immune-mediated pathologies with large
inflammatory and systemic component, where the direct transfer of AS containing elevated levels of
pro-inflammatory cytokines to the eye should be avoided [7,32].
On the other hand, ALS would allow the production of large quantities of tears, greatly improving
the logistics of the treatment and making it possible to standardize and screen the composition of
cytokines, anti-inflammatory, and epitheliotrophic components to improve their efficacy [7].
2.3. Platelet-Rich Plasma (PRP)
Under the generic term PRP is included a variety of products and denominations derived from the
patient’s own blood, which can be obtained by centrifugation to obtain a plasma fraction with a platelet
concentration higher than that in the circulating blood [33]. Platelets can be artificially activated and
release their contents housed in alpha granules, rich in a large pool of proteins and factors including
EGF, PDGF, TGF-β, secrete vascular endothelial growth factor (VEGF), IGF-1, hepatic growth factor
(HGF), nerve growth factor (NGF), and platelet factor 4 (PF-4) involved in the wound healing process
of the cornea and conjunctival surface [34,35] (Table 1).
Depending on their preparation, composition, and especially the concentration of platelets and the
presence or absence of leucocytes, different products are obtained: PDGF, plasma rich in growth factors
(PRGF), plasma rich in platelet and growth factors (PRPGF), platelet concentrate (PC), leukocyte-rich
platelet-rich plasma (LR-PRP), leukocyte-poor platelet-rich plasma (LP-PRP), among others [13,36,37].
Currently, there are more than 40 different preparation methods, which makes it difficult to
compare different scientific results in terms of both efficacy and safety [13,35,38]. Regarding the
industrialization of PRGF eye drops, there are studies of preservation and biological activity for 3
months in human use, with good outcomes in the care for patients with severe dry eye that do not
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respond to conventional therapy [39], with special success in neutrophic cases [40]. Finally, PRGF
could be used to support the growth of limbal stem cells [41,42].
PRP cellular composition defines the concentrations of growth factor and catabolic cytokine.
The platelet concentration is positively correlated with all growth factors, increasing anabolic
signaling [36,37].
Leukocytes strongly influence the quality of PRPs. Leukocytes increased catabolic signaling
molecules like matrix metallopeptidase 9 (MMP-9) that are strongly correlated with the leukocyte
concentration. There is a direct correlation between leucocytes with PDGF and the VEGF concentration,
while it is negatively correlated with fibroblast growth factor (FGF) [37].
The role of non-platelet components of whole blood contributes to their biological activity—in
particular, red and white blood cells may be detrimental by participating in unwanted inflammatory
reactions. In spite of the possible negative pro-inflammatory effect caused by the presence of
leukocyte [29,38], other studies suggest that the non-platelet cellular components are important
for optimal platelet function, including thrombin generation leading to robust coagulation, growth
factor release, and the resulting capacity of the serum to stimulate cell proliferation [36].
Different investigations have evaluated the safety and efficacy of the use of different PRP
preparations in the treatment of dry eye, demonstrating an improvement in tear film quality and
the severity of symptoms, even in patients previously treated with AS [38,39]. PRP has certain
contraindications to its use, such as serious cardiac disease in the extraction phase, active bacterial
infections, and a history of certain viral infectious diseases (B hepatitis, HIV, etc.) [35].
Therefore, depending on the clinical application, modifying the PRP preparation method should
be considered based on their ability to concentrate platelets and leukocytes with sensitivity to
pathologic conditions essential to achieve better clinical results.
2.4. Umbilical Cord Blood Serum (UCS)
Like peripheral blood serum, UCS contains a high concentration of tear components. Compared
to blood serum, concentrations of EGF and TGF-β are three and two times higher, respectively. UCS
has higher NGF and SP and lower IGF-1 and vitamin A, but it is higher than the concentration in
normal tears [29,43]. UCS shows a bacteriostatic effect because it contains antibacterial agents such as
immunoglobulin G, lysozyme, and complement [39] (Table 1).
UCS eye drops are recommended to use at 20% concentration, and are usually instilled four
to six times per day. They must be stored at −20 ◦C for 3 to 6 months [29,43]. They have been
used to treat various ocular surface diseases, including severe dry eye with or without Sjögren’s
syndrome, ocular complications in graft-versus-host disease, persistent epithelial defects, neurotrophic
keratopathy, recurrent corneal erosions, ocular chemical burn, and surface problems after corneal
refractive surgery [13,43,44].
Compared with AS eye drops, UCS eye drops have been more effective in decreasing symptoms
and have epitheliotrophic effects, increasing goblet cell density in severe dry eye syndrome [29].
A large amount of sample can be drawn from the umbilical vein at the time of delivery, so that the
requirement for several patients can be met at the same time. The risk of allergies and the possibility of
transmitting parenteral diseases must be evaluated [44].
3. Stem Cell Therapy
In the last decade, there has been an emerging interest in stem cell therapy for different pathologies,
including ocular diseases [45–48]. Among all cell candidates to be employed, mesenchymal stem cells
or multipotent stromal cells (MSCs) have been the most interesting for researchers [46,49].
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3.1. MSCs (Auto/Allogeneic)
MSCs are currently proposed as cell therapy for many diseases, particularly those with an
inflammatory and immunomediated component. There are over 740 clinical trials now listed at
www.clinicaltrials.gov using MSCs. Autologous and allogenic cell therapies are now ongoing.
MSCs are a group of fibroblast-like self-renewing, non-hematopoietic, multipotent progenitor cells,
and are ontogenically derived from the embryonic layer of the mesoderm. The International Society
for Cellular Therapy has suggested minimal criteria to define the MSC: they are plastic-adherent, must
present a certain surface molecule profile and be able to differentiate to at least three mesenchymal
lineages (osteogenesis, adipogenesis, and chondrogenesis) [50]; in addition, they must maintain
their immunomodulatory potential [51]. Due to a lack of major histocompatibility complex II
(MHC-II) expression and co-stimulatory molecules (such as CD40, CD80, and CD86), they can be used
allogenetically since they escape the recognition and action of T cells and natural killer (NK) cells [52].
They fulfil a function as a reservoir of undifferentiated cells for the regeneration of the tissues
where they are located, having been isolated in diverse adult or extraembryonic tissues [53,54].
They present the migration and homing capacity to the site of the lesion in response to the cytokines,
chemokines, and growth factors released [55,56]. In addition, they do not raise ethical issues and have
very low tumorigenesis potential [57–60].
Different mesenchymal stem-like cell populations have been identified in the eye: basal limbus,
corneal stroma, trabecular meshwork, choroids, and periorbital fat [47,61,62]. MSCs can differentiate
both towards mesenchymal lineages and other germ lines [58,59], among them different cell types
present in the corneal surface such as epithelial, stromal, and endothelial [55,60,63].
Actually, it is well established that the ability to modulate the immune system plays a fundamental
role in almost all the therapeutic effects attributed to these cells, rather than their capacity of
differentiation in different cell lineages [54,60,64,65]. This property is carried out through the release
of a large variety of bioactive substances with autocrine and paracrine effects, encompassed under the
concept of the secretome [56,66]. There are included a huge variety of molecules, including proteins,
growth factors, antioxidants, proteasomes, microvesicles, and exosomes, which target a multitude
of biological targets (pleiotropic effect) [67,68], and are responsible for different effects: production
of extracellular matrix, antiapoptotic, antifibrotic, chemoattractive, neuroprotective, morphogenic,
angiogenic, antimicrobial, immunomodulatory, etc. [56,69,70]. The composition of the secretome and
its immunomodulatory capacity varies with the species, source method of manufacture, medication,
and microenvironment where the MSCs are homeing [49,54,71].
The immunomodulatory effect of MSCs is exerted on both the innate and adaptive immune
response, through different mechanisms such as direct cell-to-cell contact and the secretion of different
soluble substances in their secretome [65]. In particular, the indolamine 2,3-dioxygenase (IDO),
prostaglandin E2 (PGE2), TGF-β, HGF, nitric oxide (NO), IL-1, IL-6, and interleukin 1 receptor
antagonist, among others [64,65,72]. However, their immunomodulatory mechanism is not restricted
to soluble factors. Recently, it has been shown that the exosomes excreted by MSCs modulate the
inflammatory response, in addition to other functions via direct action on resident cell targets [67,72,73].
Regarding innate immunity, MSCs have demonstrated the ability to modulate different types
of cells that constitute this first line of defense, such as macrophages, neutrophils, dendritic cells,
and NK [54,65,72,74]. Regarding adaptive immunity, they demonstrate a very interesting aspect of
immunomodulation, due to their broad action capacity on Th1, Th2, and Th17 responses [54,65,75,76].
It is considered that one of the major MSCs’ immunomodulation mechanisms is the regulation
of T cells—both CD4+ and CD8+—by cell-to-cell contact and inhibitory molecules of their
secretome [54,67,76]. They are also able to act on B cells by modifying their activation, proliferation,
chemotactic response, and differentiation to becoming antibody-secreting plasma cells [54,65,75,76].
The immunomodulatory capacity of MSCs is also complemented by their important potential to
promote the generation and maintenance of the activity of different types of regulatory T cells [54,67,75].
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Regulatory T cells are cell mediators of peripheral immunological tolerance, and their absence results
in excessive multisystem autoimmunity [77,78].
MSCs implantation by different routes has raised very interesting expectations in the treatment of dry
eye and regeneration of the ocular surface, thanks to their capacities of immunomodulation and regenerative
potential [78,79]. MSC therapy in experimental DES syndrome models improved tear volume and tear
film stability, increasing epithelial recovery and the number of goblet cells and decreasing the number of
meibomian gland injuries in the conjunctiva [77,80]. Decreasing CD4+ T cells and proinflammatory factors
(IL-2, interferon-gamma (IFN-γ), IL-17, and MMP-2) and increasing anti-inflammatory T cell responses
augments the regulatory T cells, preventing the progression of the process [80].
Somewhat more than half of human patients with refractory dry eye secondary to chronic
graft-versus-host disease (GVHD) treated with MSCs showed reduced symptoms with improved dry
eye scores, which suggests that MSCs regulate the balance between Th1 and Th2 [81].
Our group was the first to demonstrate the clinical efficacy of periglandular implanted allogeneic
MSCs in a canine model. Canines are a superior preclinical animal model, suffering the disease in
a natural way similar to humans, avoiding the use of other induced animal models, far from the
immune-mediated component of this pathology [82] (Figure 1).
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Figure 1. Results of periglandular MSCs (mesenchymal stem cells or multipotent stromal cells)
implantation in severe and refr ctory canine keratoconjunctivitis sicca. (a) Before implantation; (b) After
9 months of treatment.
We demonstrated that the MSCs periglandular implantation of the lacrimal glands was an easy
and effective system in the functional restoration, with therapeutic response for at least one year,
increasing tear secretion and restoring the inherent clinical signs of the disease in dogs refractory to
conventional treatment [82]. Similar results have subsequently been reported [83] (Figure 2).
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Another interesting aspect was to use allogeneic cells as a therapeutic element. There is increasing
evidence that factors such as the age or concomitant diseases affect the efficacy of MSCs [84–86].
DED is a pathology that fundamentally affects aged patients and is often accompanied by other
immunomediated processes, where the allogeneic therapy presents a great advantage [35–37].
This allows the use of perfectly characterized cells in the laboratory from healthy controlled donors
and simplifies the logistics for delivery and transplantation [82]. In severe DED, there is damage of the
corneal surface [4,9,10]. The damage of the corneal epithelial cell layer and the deeper stromal layer
involves a healing process mediated by the activation of progenitor cells that are found in the limbal
region of the cornea: the limbal epithelial stem cells (LESCs) [62,78]. Extensive loss of LESCs leads to a
persistent corneal epithelial defect and corneal conjunctivalization [79,87].
The importance of the limbal niche in the regeneration of the corneal surface has been perfectly
described, where in addition to the existence of a population of limbal epithelial stem/progenitor cells
responsible for corneal differentiation, there is a population of MSCs located underneath them with an
important role in the regeneration of the corneal surface [62].
Currently LESCs transplantation is the only European Medicines Agency (EMA) authorized
cellular therapy for the repair of lesions of the corneal surface. This is possible in unilateral disease,
when the contralateral cornea is healthy or less damaged. However, there is a risk of limbal stem cell
deficiency development in the donor eye. Allogeneic limbal transplantation has been conducted by a
number of ophthalmologists; however, results were not satisfactory, and treatment requires prolonged
immunosuppressive therapy [60]. Additionally, the use of MSCs in different models and routes of
administration has aroused great expectation in corneal wound healing, decreased conjunctivalization,
corneal opacity, inflammation and the area of neovascularization [60,80].
The transplanted MSCs enhanced corneal wound healing by trophic factor production and immune
regulatory effect, rather than by direct transdifferentiation into corneal cells [49,62,87]. Corneal scarring
is the main complication of corneal wound healing. Corneal fibroblasts (activated stromal keratocytes)
migration and their response are modulated by various cytokines and growth factors, which are
significantly inhibited by MSCs. The antiscarring capacity of MSCs has been widely reported [49,87].
MSCs have been shown to be good activators of angiogenesis and secrete VEGF [88,89]. However,
MSCs seemed to have an opposite effect on corneal angiogenesis, upregulated the expression of
thrombospondin-1 (TSP-1, a powerful antiangiogenic factor), and significantly downregulated MMP-2,
an inflammation-related proangiogenic factor [90].
In conclusion, based on the multiple effects such as anti-inflammatory, immunomodulatory,
antiangiogenic, tear production, and corneal wound healing (reduce neutrophil and macrophage
infiltration, help epithelial recovery, decreased number of meibomian gland injuries in the
conjunctiva, and increasing number of goblet cells), MSCs are a promising source to treat dry eye
syndrome [63,82,90] (Figure 1).
3.2. MSCs Secretome
As discussed above, many of the MSCs’ action mechanisms are carried out through the release
of a wide variety of bioactive substances encompassed under the concept of the secretome [56,66,70].
The secretome is composed of soluble factors and extracellular vesicles, as microvesicles or
exosomes [55,69]. It is thought to be encoded by approximately 10% of the human genome [91,92].
The secretome plays a crucial role as mediators in cell-to-cell interactions and with the surrounding
tissues, in functions such as proliferation, differentiation, communication, and migration [56,68].
In recent years, a large number of studies have focused on characterization of the stem cell secretome
and have shown great potential in a variety of clinical applications as a cell-free option for regenerative
medicine therapies. Ocular surface pathologies are an excellent objective for such a therapy [70,91–94].
The experimental topical instillation of the secretome in ocular diseases has shown significant
improvement in corneal wound healing, attenuating corneal inflammation by inhibition of the
proinflammatory cytokines and infiltration of inflammatory cells [94,95]. In allergic conjunctivitis,
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anti-allergic effects were shown with a reduction of inflammatory cell conjunctival infiltration,
inhibition of B cells, mast cells, and histamine functions, through a COX-2-dependent mechanism [96].
The future advantages of the use of the secretome in superficial ocular diseases is to prevent some of
the undesirable effects associated with the traditional use of stem cells in regenerative medicine therapy,
including reduced concerns for oncogenic potential, lack of immunogenic reaction enabling allogeneic use,
and the transmission of infections [68,70]. From the logistic point of view, it could be prepared in advance
in large quantities, allowing its long-term storage and immediate delivery for treatment. Stem cells
could be considered as tunable pharmacological storehouses useful for combinatorial drug manufacture,
delivery, and could be adjusted for different clinical applications [92,96].
4. Conclusions
Despite the large number of therapeutic strategies in the management of DED, in recent years new
regenerative therapies have consolidated a new perspective in the management of this complex disease,
such that it is necessary to have standardization and comparison of their results. This represents
an important gateway of hope in the treatment of these pathologies, and an opportunity for further
development of pharmacological and cell therapy interventions.
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TGF-β Transforming growth factor-beta
PDGF Platelet-derived growth factor
EGF Epidermal growth factor
NGF Nerve growth factor
IGF-1 Insulin-like growth factor 1
VEGF Vascular endothelial growth factor
SP Substance P
PRP Platelet-rich plasma
UCS Umbilical cord blood serum
IL Interleukin
TNF-α Tumor necrosis factor-α
CGRP Calcitonin gene-related peptide
ALS Allogeneic serum
HGF Hepatocyte growth factor
PF-4 Platelet factor-4
PRGF Plasma rich in growth factors
PRPGF Plasma rich in platelet and growth factors
PC Platelet concentrate
LR-PRP Leukocyte-rich platelet-rich plasma
LP-PRP Leukocyte-poor platelet-rich plasma
MMP-9 Matrix metallopeptidase 9
MSCs Mesenchymal stem cells or multipotent stromal cells
MHC-II Major histocompatibility complex II
NK Natural killer cells
IDO Indolamine 2,3-dioxygenase
PGE2 prostaglandin E2
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IFN-γ Interferon-gamma
LESCs Limbal epithelial stem cells
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